GlucoTrack, Inc. (GCTK) 股票分析

公司概述

GlucoTrack, Inc. operates as a medical device company dedicated to the development of implantable continuous blood glucose monitors (CBGM) designed specifically for the diabetic population within the United States market. This enterprise functions within the broader Healthcare sector, specifically categorized under the Medical Instruments & Supplies industry, which implies a focus on essential diagnostic and therapeutic technologies for chronic disease management. The company currently maintains a market capitalization of $1.26M, while reported annual revenue (TTM) and employee count are listed as N/A in the available data. These valuation figures indicate that GlucoTrack is a micro-cap entity, suggesting it operates at an early-stage scale where market capitalization is heavily influenced by development potential rather than established revenue streams or operational workforce size.

财务健康

The financial statements for GlucoTrack, Inc. report a Net Income (TTM) of $-19,388,000 and an EBITDA of $-16,048,000, while Revenue (TTM) is not disclosed, highlighting a significant gap between top-line activity and profitability that reveals a cost structure dominated by high research and development expenditures or operational burn rates typical of biotech firms. The company's Free Cash Flow stands at $-9,444,875, indicating that the organization is currently consuming cash reserves to fund its operations and product development rather than generating surplus liquidity for debt repayment or shareholder returns. Analysis of the three primary margins shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, collectively indicating that the company has not yet achieved operational profitability or scaled revenue sufficiently to cover its variable and fixed costs. Regarding balance sheet leverage, GlucoTrack holds $7.38M in cash against $3.45M in debt, resulting in a Debt to Equity ratio of 121.85, which suggests a highly leveraged capital structure relative to its equity base despite the positive cash position. The Current Ratio is reported at 1.61, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate level of short-term liquidity safety. Furthermore, the Return on Equity is listed as N/A and the Return on Assets is -146.1%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or the company's asset base.

估值评估

Valuation multiples for GlucoTrack, Inc. present a mixed picture, with the Trailing P/E and Forward P/E both listed as N/A due to the lack of positive net income required to calculate these standard profitability metrics. The Price to Book ratio is 0.21, indicating that the market values the company's equity at a significant discount to its net asset value, a common characteristic for distressed or pre-revenue biotech firms. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (0.17) are utilized to assess the firm, where the low EV/EBITDA of 0.17 reflects the company's negative earnings and suggests the market is pricing the stock based on asset liquidation value or future optionality rather than current cash flows. The stock price has exhibited significant volatility over the past year, trading between a 52-Week High of $15.90 and a 52-Week Low of $0.62, meaning the current market price sits within a range that reflects high uncertainty and speculative trading behavior. The Beta value is 0.61, which implies that the stock's price volatility is lower than the broader market, suggesting it may move less dramatically than the overall market index during periods of systemic risk or economic shifts.

Growth & Income

Growth metrics for GlucoTrack, Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, reflecting the company's stage of development where historical growth rates are not yet established or available for analysis. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all generated cash flow, if any, or existing capital reserves are being reinvested into the business operations and product development rather than distributed to shareholders. Since the company does not pay dividends, the growth profile is entirely dependent on successful product commercialization and the eventual transition from negative net income to profitability, which is essential for sustaining the current business model. The overall growth and income profile is characterized by a complete absence of current earnings generation and dividend distribution, placing the entire investment thesis on the future success of the GlucoTrack device in the diabetes monitoring market.